radiotheranostics based on chemical control of radioactivity pharmacokinetics
Several drugs are in advanced clinical trials: In Phase III trials: IBI362 (Innovent/Eli Lilly), CagriSema (Novo Nordisk), Retatrutide (Eli Lilly), and Survodutide (Boehringer Ingelheim)
Until then, the notification said GLP-1 RAs should only be prescribed for their licensed indication, and clinicians should avoid initiating people with T2DM on GLP-1 RAs for the duration of the national shortage
Compounded semaglutide and tirzepatide are pharmacy-prepared formulations of the same active ingredients found in Wegovy, Ozempic, Zepbound, and Mounjaro
According to stability studies for the fabricated nanosystems, it was concluded that nanovesicular carriers may provide a protective core for active products, preventing them from being exposed to environmental conditions